TABLE 3.

Variables associated with survival (overall or recurrence-free) after liver transplantation for hepatocellular carcinoma

	Univariable		Multivariable		Final
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Overall survival
HCC group
Low-risk, no adjuvant sorafenib	Reference		Reference
High-risk, no adjuvant sorafenib	1.35 (0.74-2.46)	0.32	0.99 (0.50-1.98)	0.98
Adjuvant sorafenib	2.18 (0.89-5.37)	0.09	1.31 (0.45-3.78)	0.62
Age at transplant, y	1.03 (0.99-1.08)	0.15	1.03 (0.98-1.07)	0.26
AFP at referral, ng/mL	1.00 (1.00-1.00)	0.56	1.00 (1.00-1.00)	0.62
Neoadjuvant LRT
No	Reference		Reference
Yes	1.75 (0.69-4.41)	0.24	1.81 (0.71-4.65)	0.22
No. of tumor modules	1.01 (0.98-1.05)	0.43	0.98 (0.94-1.03)	0.55
Maximum tumor diameter, cm	1.12 (1.03-1.23)	0.01	1.12 (0.98-1.28)	0.11	1.09 (0.99-1.19)	0.07
Lymphovascular invasion
Absent	Reference		Reference		Reference
Present	2.75 (1.40-5.40)	0.003	2.23 (0.97-5.13)	0.06	2.35 (1.15-4.80)	0.02
Recurrence-free survival
HCC group
Low-risk, no adjuvant sorafenib	Reference		Reference		Reference
High-risk, no adjuvant sorafenib	4.21 (1.65-10.76)	0.003	2.90 (1.05-7.95)	0.04	3.19 (1.20-8.45)	0.02
Adjuvant sorafenib	8.05 (2.45-26.38)	<0.001	5.66 (1.51-21.16)	0.01	6.99 (2.12-23.05)	0.001
Age at transplant, y	1.00 (0.95-1.05)	0.93	0.99 (0.94-1.05)	0.72
AFP at referral, ng/mL	1.00 (1.00-1.00)	0.73	1.00 (1.00-1.00)	0.67
Neoadjuvant LRT
No	Reference		Reference
Yes	1.67 (0.50-5.56)	0.40	1.66 (0.47-5.85)	0.43
No. of tumor modules	1.03 (1.00-1.07)	0.04	0.99 (0.94-1.04)	0.64
Maximum tumor diameter, cm	1.24 (1.13-1.37)	<0.001	1.20 (1.02-1.41)	0.03	1.19 (1.07-1.33)	0.002
Lymphovascular invasion
Absent	Reference		Reference
Present	4.19 (1.83-9.60)	<0.001	1.77 (0.67-4.64)	0.247

Bold values denote P < 0.05.

AFP, alpha-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; LRT, locoregional therapy.